

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 434. (Canceled)

435. (Currently Amended) A fusion protein that binds CD20 ~~The fusion protein of claim 414 wherein the fusion protein comprises~~ comprising an amino acid sequence as set forth in:

SEQ ID NO:135 (2H7 scFv (CSS-S)H WCH2 WCH3), wherein proline at position 283 is substituted with serine;₅

SEQ ID NO:137 (2H7 scFv (SCS-S)H WCH2 WCH3), wherein proline at position 283 is substituted with serine;₅

SEQ ID NO:166 (2H7 scFv (CSC-S)H WCH2 WCH3), wherein proline at position 283 is substituted with serine;₅

SEQ ID NO:372 (2H7 scFv VHL11S (CSS-S)H WCH2 WCH3);₅

SEQ ID NO:246 (2H7 scFv VH L11S (CSC-S)H WCH2 WCH3);₅

SEQ ID NO:370 (2H7 scFv VH L11S (SSS-S)H WCH2 WCH3);₅

SEQ ID NO:268 (2H7 scFv VH L11S (CSS-S)H K322S CH2 WCH3);₅ or

SEQ ID NO:276 (2H7 scFv VH L11S (CSS-S)H P331S CH2 WCH3).

436. (Currently Amended) A fusion protein that binds CD20 ~~The fusion protein of claim 414 wherein the fusion protein consists~~ consisting essentially of an amino acid sequence as set forth in SEQ ID NO:135 (2H7 scFv (CSS-S)H WCH2 WCH3) wherein proline at position 283 is substituted with serine, SEQ ID NO:166 (2H7 scFv (CSC-S)H WCH2 WCH3) wherein proline at position 283 is substituted with serine, SEQ ID NO:372 (2H7 scFv VHL11S (CSS-S)H WCH2 WCH3), or SEQ ID NO:246 (2H7 scFv VH L11S (CSC-S)H WCH2 WCH3).

437. (Canceled)

438. (Currently Amended) A fusion protein comprising from amino-terminus to carboxy-terminus: (i) an scFv binding domain polypeptide that binds CD20, wherein the scFv comprises an immunoglobulin light chain variable region polypeptide consisting of amino acids 23-128 as set forth in SEQ ID NO:689, a linker peptide consisting of amino acids 129-144 as set forth in SEQ ID NO:246, and an immunoglobulin heavy chain variable region polypeptide consisting of amino acids 145-265 as set forth in SEQ ID NO:689, wherein leucine 155 of the heavy chain variable region polypeptide is substituted with serine; (ii) an immunoglobulin hinge polypeptide consisting of amino acids 267-283 as set forth in SEQ ID NO:246; and (iii) an amino-terminally truncated immunoglobulin heavy chain constant region polypeptide consisting of amino acids 284-500 as set forth in SEQ ID NO:246.

439. (Currently Amended) A pharmaceutical composition comprising a ~~binding domain-immunoglobulin fusion protein according to claim 414-435 in combination with~~ and a physiologically acceptable carrier.

440.-445. (Canceled)

446. (New) A pharmaceutical composition comprising a fusion protein according to claim 436 and a physiologically acceptable carrier.

447. (New) A pharmaceutical composition comprising a fusion protein according to claim 438 and a physiologically acceptable carrier.